Complex biological systems interact with the environment to achieve homeostasis – the physiological stability needed to sustain life. From basic functions that maintain normal body temperature regulation to calibrated immune signaling to fight disease, our bodies seek equilibrium to survive and thrive. Autoimmune and inflammatory diseases result from dysregulation of the healthy immune response, rooted in either the adaptive or innate immune systems. They include many debilitating and life-threatening conditions, affecting every organ system and causing dramatically decreased quality of life and significant morbidity and mortality for tens of millions of patients worldwide. For many autoimmune and inflammatory diseases, treatment options are inadequate or absent altogether. Systemic immunomodulators can help manage some inflammatory and autoimmune diseases, but they often deliver inadequate efficacy and are associated with treatment-limiting side effects that can be severe.
To meet the need for therapies that safely address underlying immune dysregulation, Q32 Bio has developed an integrated portfolio of therapies to modulate the innate and adaptive immune responses. Our team’s mission is to bring safer, more efficacious therapeutics to patients suffering from a wide range of devastating autoimmune and inflammatory diseases, starting with those rooted in the complement system and interleukin-7 (IL-7) signaling pathways. In pursuit of our bold vision, Q32 Bio has assembled leaders in the field of immunology uniquely positioned to develop novel biologics based on the body’s innate and adaptive immune systems. Our lead molecules include therapeutic fusion proteins that deliver negative regulators of complement activation directly to disease-affected tissues and a monoclonal antibody antagonist of the interleukin-7 receptor (IL-7R).
Cambridge, Mass. – August 3, 2021 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Kathy LaPorte to its Board of Directors. Ms. LaPorte, who brings over 30 years of experience in executive leadership and venture investing within the biotech industry, will serve as the Chair […] Read More >
Cambridge, Mass. – July 7, 2021 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Adam Cutler as Chief Financial Officer. Mr. Cutler will be responsible for all aspects of Q32’s financial strategy and operations. Read More >
Cambridge, Mass. – May 27, 2021 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that Michael Broxson, Chief Executive Officer, will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:30 pm ET. Read More >
Cambridge, Mass. (March 9, 2021) – Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of Jason Campagna, M.D., Ph.D. as Chief Medical Officer. Dr. Campagna brings more than 15 years of biotech and pharmaceutical experience to the Q32 Bio executive team during a critical growth and development period for the company. Read More >
Cambridge, Mass. (December 22nd, 2020) – Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of industry leader Mark Iwicki as Chairman of their Board of Directors. Mr. Iwicki will succeed Dr. David Grayzel as Chairman. Dr. Grayzel, an Atlas Venture partner and co-founder of Q32, will continue as a Director. Read More >
Cambridge, Mass. (October 29, 2020) – Q32 Bio, a biotechnology company developing biologic therapeutics to restore healthy immune regulation, today announced the completion of a $60 million Series B financing co-led by OrbiMed Advisors and Acorn Bioventures. The company also announced the commencement of a Phase 1 clinical trial evaluating its best-in-class IL-7R antibody ADX-914, a significant milestone marking Q32 Bio’s entry into clinical-stage development. Read More >
Proprietary tissue-targeted complement platform and best-in-class IL-7R antibody technology to treat patients with severe autoimmune and inflammatory disease; clinical trials begin in 2020 Read More >